Study wrapper · #922
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V High blood pressure & cardiovascular prevention. 2026.
DOI: 10.1007/s40292-026-00812-6PubMed: 42371360
Editor's note
This meta-analysis pools randomized controlled trials, giving it relatively strong evidentiary weight for retatrutide's cardiometabolic effects. It reports consistent reductions in blood pressure and atherogenic lipids, with heterogeneity noted for cholesterol outcomes. Findings are association-based from a drug still under clinical development.
Plain-language abstract
A meta-analysis of randomized trials found retatrutide was associated with lower systolic and diastolic blood pressure and reduced total cholesterol, LDL cholesterol, and triglycerides, with no significant change in HDL.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Annals of internal medicinen=——2026